Gabapentin Tablets — Class III drug recall D-0354-2023
Terminated recall by Sciegen Pharmaceuticals Inc, reported 2023-03-08, distributed nationwide. Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled
| Recall number | D-0354-2023 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Sciegen Pharmaceuticals Inc, Hauppauge, NY, United States |
| Recall initiated | 2023-02-17 |
| Classified | 2023-02-27 |
| Reported by FDA | 2023-03-08 |
| Terminated | 2024-06-17 |
| Distributed | Nationwide (US) |
| Quantity | 4,392 bottles |
| NDC | 50228-0177, 50228-0177-01, 50228-0177-05, 50228-0177-30, 50228-0178, 50228-0178-01, 50228-0178-05, 50228-0178-30 |
| Lot numbers | 11/24, G177092 |
Product
Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY 11788, NDC: 50228-177-05.
Reason for recall
Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0354-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.